Written by The Biopsy Devices Market serves numerous clinical applications, with oncology representing one of the most important sources of demand. Tissue biopsy remains essential for confirming many cancers and determining characteristics that influence treatment selection. Breast biopsy was the largest application segment in 2025, accounting for approximately 33.4% of market revenue, supported by established mammography screening and follow-up diagnostic pathways. Prostate biopsy is also becoming increasingly sophisticated as MRI-fusion technologies allow physicians to target suspicious lesions more accurately. Liver biopsy continues to be used in selected diagnostic and staging applications, while gynecological biopsy procedures support the evaluation of abnormal cervical and other reproductive-system findings. Lung biopsy is expected to experience particularly strong growth, with MRFR projecting a CAGR of 9.70% through 2035 as low-dose CT screening programs increase the number of suspicious pulmonary lesions requiring tissue confirmation.
The expansion of minimally invasive healthcare is creating additional demand for biopsy technologies that can provide reliable diagnostic information while reducing patient trauma and recovery time. Image-guided biopsy procedures are increasingly preferred when lesions can be targeted without extensive surgery. Ultrasound-guided systems are widely used for accessible lesions, while CT and MRI guidance can support more complex procedures. Stereotactic systems are particularly important in breast diagnostics. Hospitals represented approximately 63.4% of end-user spending in 2025, reflecting their role in performing complex image-guided procedures. However, diagnostic and imaging centers and ambulatory surgical centers are gaining importance as procedures move toward outpatient environments. The growth of screening programs, aging populations, and increasing cancer awareness is expected to increase the number of patients requiring diagnostic tissue sampling. At the same time, improvements in biopsy device design can help physicians obtain adequate samples with fewer complications. Emerging rapid tissue-analysis technologies may eventually shorten the time between sample acquisition and preliminary diagnostic assessment. Increasing Market Demand is therefore expected to be supported by cancer screening, minimally invasive diagnostic procedures, improved imaging technologies, and wider access to pathology services.